CPC
HRTX icon

Congress Park Capital’s Heron Therapeutics HRTX Stock Holding History

Congress Park Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-300
Closed -$6K – 132
2020
Q4 		$6K Buy
+300
New +$5.21K ﹤0.01% 113
2020
Q2 		– Sell
-200
Closed -$2K – 94
2020
Q1 		$2K Buy
200
+100
+100% +$1.88K ﹤0.01% 87
2019
Q4 		$2K Buy
+100
New +$2.21K ﹤0.01% 97

Other funds holding HRTX

AR
Apeiron RIA Dallas, Texas $440M AUM 15.34% 1-Year Est. Return
DIM
DLK Investment Management Solana Beach, California $275M AUM 10.69% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
DI
DDFG Inc Thousand Oaks, California $508M AUM 11.76% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
AA
ACT Advisors Asheville, North Carolina $308M AUM 16.31% 1-Year Est. Return
Dynamic Advisor Solutions
Dynamic Advisor Solutions Phoenix, Arizona $3.52B AUM 15.33% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $2.57B AUM 28.13% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Congress Park Capital's HRTX Position: Q3 2026 in Review

Congress Park Capital reduced its Heron Therapeutics (HRTX) stake by 73% in Q3 2026, selling an estimated $555K and leaving 551,697 shares worth $173K. The position accounts for 0.05% of the portfolio, ranked #127.

Congress Park Capital first reported a position in HRTX in Q4 2017 and has held it in 36 quarters since. The position peaked at $5.52M in Q2 2024. 14 funds tracked by Wall St. Rank hold HRTX as of Q3 2026.

  • Congress Park Capital held 551,697 shares of Heron Therapeutics worth $173K as of Q3 2026.
  • Congress Park Capital sold 1,464,750 Heron Therapeutics shares in Q3 2026, an estimated $555K.
  • Heron Therapeutics made up 0.05% of Congress Park Capital's portfolio in Q3 2026, its #127 holding.
  • Congress Park Capital first reported a position in Heron Therapeutics in Q4 2017 and has held it in 36 quarters since.
  • Congress Park Capital's Heron Therapeutics position peaked at $5.52M in Q2 2024.
  • 14 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2026.

Based on Congress Park Capital's 13F filing for Q3 2026, filed 13 Oct 2026.